Can B cell-deficient patients rely on COVID-19 vaccine-induced T-cell immunity?
Can B cell-deficient patients rely on COVID-19 vaccine-induced T-cell immunity?
复制标题
B 细胞缺陷患者能否依赖 COVID-19 疫苗诱导的 T 细胞免疫？
DOI：
10.1111/bjh.18210
复制
发表时间：
2022
影响因子：
6.5
通讯作者：
Shree,Tanaya
中科院分区：
文献类型：
--
作者：
Shree,Tanaya
抗CD 20抗体治疗可预防针对严重急性呼吸综合征冠状病毒-2（SARS-CoV-2）疫苗的体液应答，但在这种情况下T细胞应答的性质尚不清楚。Riise等人在最近接受利妥昔单抗治疗的淋巴瘤患者中评估了疫苗诱导的表位特异性CD 8 T细胞应答，并发现了广泛的应答，最近接受治疗的患者通常没有应答，而其他患者的应答比健康对照组更强。他们建议这些表位可以用于T细胞靶向疫苗，并且这种策略现在确实在临床试验中。评论：Riise J，et al.利妥昔单抗治疗的淋巴瘤患者在COVID-19疫苗接种后产生强烈的CD 8 T细胞应答。英国血液学杂志. 2022;197：697 - 708
Anti‐CD20 antibody treatments prevent humoral responses to vaccines against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) vaccines, but the nature of T‐cell responses in this setting is less well understood. Riise et al. assess vaccine‐induced epitope‐specific CD8 T cell responses in patients with lymphoma recently treated with rituximab and find a wide range of responses, with the most recently treated patients frequently failing to respond, while others exhibit responses stronger than healthy controls. They suggest these epitopes among others could be used in a T cell‐targeted vaccine, and such strategies are indeed in clinical trials now.Commentary on: Riise J, et al. Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination. Br J Haematol. 2022;197:697‐708